高级检索
    梁乃新, 梅世琪. 埃克替尼在伴有EGFR敏感突变Ⅱ~ⅢA期非小细胞肺癌术后辅助治疗的应用[J]. 循证医学, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
    引用本文: 梁乃新, 梅世琪. 埃克替尼在伴有EGFR敏感突变Ⅱ~ⅢA期非小细胞肺癌术后辅助治疗的应用[J]. 循证医学, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
    shu
    LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
    Citation: LIANG Nai-xin, MEI Shi-qi. The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 34-37. DOI: 10.12019/j.issn.1671-5144.2022.01.008
    shu

    埃克替尼在伴有EGFR敏感突变Ⅱ~ⅢA期非小细胞肺癌术后辅助治疗的应用

    The Application of Icotinib as Adjuvant Therapy for Stage Ⅱ~ⅢA EGFR-Mutant Non-Small-Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回